

10/568136

LAP20 Rec'd PCT/PTO 09 FEB 2006

"Express Mail" mailing label number <u>EV 393128654 US</u>	
Date of Deposit <u>FEB. 09, 2006</u>	
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>QUEEN THOMAS</u> Printed Name	<u>Queen Thomas</u> Signature

**PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant: GALKA Christopher Stanley

For: 6-(2,2,2-TRIFLUOROETHYLAMINO)-7-CHLORO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINE AS A  
5-HT<sub>2C</sub> RECEPTOR AGONIST

Docket No.: X16357

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.


Applicants request consideration of this information.

Respectfully submitted,



R. Craig Tucker  
Attorney for Applicants  
Registration No. 45,165  
Phone: 317-433-9829

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288



FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16357	Serial No. <b>10/568136</b>
	First Applicant GALKA Christopher Stanely	
	Filing Date US Nat'l Entry (if applicable)	Group

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 4,100,278	July 11, 1978	Nedelec, et al	
	AB	US 4,265,890	May 5, 1981	Holden, et al	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 02/074746 A1	Mar. 12, 2002			
	BB	WO 03/045940 A2	Nov. 26, 2002			
	BC	WO 03/099792 A1	May 28, 2003			
	BD	WO 03/086306 A2	Apr. 11, 2003			
	BE	GB1225053	Aug. 14, 1968			
	BF	WO 03/006466 A1	July 10, 2002			
	BG	WO 93/03015	Aug. 5, 1992			
	BH	WO 93/04686	Sep. 11, 1992			
	BI	EP 0 285 287 A2	Mar. 17, 1988			
	BJ	EP 1 213 017 A2	Dec. 6, 2002			
	BK	WO 93/00094	June 17, 1992			

Examiner Signature	Date Considered
-----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-16357	Serial No. <b>10/568136</b>
	First Applicant GALKA Christopher Stanely	
	Filing Date US Nat'l Entry (if applicable)	Group

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T <sup>6</sup>
	CA	S.P. Vickers, et al., "Oral administration of the 5-HT <sub>2C</sub> receptor agonist, mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia" <u>Psychopharmacology</u> (2003) 167:274-280	
	CB	Tecott, et al., "Eating disorder and epilepsy in mice lacking 5-HT <sub>2C</sub> serotonin receptors" <u>Nature</u> (1995), Vol. 374, 542-546	
	CC	Upton, et al., "Studies on the role of 5-HT <sub>2C</sub> and 5-HT <sub>2B</sub> receptors in regulating generalized seizure threshold in rodents" <u>Euro. J Pharmacology</u> (1998), 359:33-40	
	CD	Chou-Green, et al., "Compulsive behavior in the 5-HT <sub>2C</sub> receptor knockout mouse" <u>Physiology &amp; Behavior</u> (2003), 78:641-649	
	CE	Martin, et al., "Influence of the 5-HT <sub>2C</sub> receptor antagonist, SB-242084, in tests of anxiety" <u>Pharmacology Biochemistry and Behavior</u> (2002) 71:615-625	
	CF	Leysen, et al., "Ligands for the 5-HT <sub>2C</sub> Receptor as potential Antidepressants and Anxiolytics" <u>Trends in Drug Research II</u> (1998), 29:49-61	
	CG	Frank, et al., "Sleep and Sleep Homeostasis in Mice Lacking the 5-HT <sub>2C</sub> Receptor" <u>Neuropsychopharmacology</u> (2002) 27(5):869-873	
	CH	Fitzgerald, et al., "Chapter 3: 5-HT <sub>2C</sub> Receptor Modulators: Progress in development of New CNS Medicines" <u>Annual Reports in Med. Chem</u> (2002) 37:21-30	
	CI		
	CJ		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of

document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.